PIK3CA and breast cancer: Breast cancer patients with low COX-2 expression and PIK3CA wild type tumors had worse DFS compared to all other subgroups in celecoxib treatment, which suggest COX-2 expression and PIK3CA mutation may be good prognostic and predictive biomarkers for celecoxib therapy [88].